In a note to investors on Monday, Larry Biegelsen, a medical device analyst at Wachovia, wrote that there was "no sign of ENHANCE" on the schedule for the meeting.

FORBES: Magazine Article

But in a note to investors yesterday, Larry Biegelsen at Wachovia Securities wrote that he expects Cordaptive to take more than 50% of the niacin market, slowing Abbott's growth.

FORBES: Magazine Article

The researchers in the trial did not link this death to tofacitinib, but it according to Wells Fargo analyst Larry Biegelsen it is the fourth death of a patient from heart failure.

FORBES: Pfizer's Key Drug Walks A Tightrope